GlassScriptPhysician profile
Nicole M Kish
NPI 1952334906
$4,645.55
in general payments reported to CMS, 2019-2025
26 companies · $906 in 2025
The $906 reported for 2025 was more than what 89% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,119 · 2020: $433 · 2021: $520 · 2022: $664 · 2023: $564 · 2024: $441 · 2025: $906.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,738 · Entertainment: $171.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,738.31 |
| Entertainment | $171.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,063.25 | 2019-2025 | Precision7, Precision 1, Dailies |
| Glaukos Corporation | $785.48 | 2019-2025 | Idosetr, Istent Infinite, Ce-Marked Kxla System |
| Optos, INC. | $378.90 | 2019-2024 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Optovue, INC. | $373.99 | 2019 | |
| Johnson & Johnson Vision Care, INC. | $308.22 | 2019-2025 | |
| Bausch & Lomb Americas INC. | $270.54 | 2022-2025 | Miebo, Xiidra, Vyzulta |
| Abb Con-Cise Optical Group LLC | $161.64 | 2019 | |
| Sight Sciences, INC. | $140.93 | 2022-2025 | Tearcare System |
| Kala Pharmaceuticals, INC. | $139.71 | 2021-2022 | |
| Sun Pharmaceutical Industries INC. | $138.33 | 2023 | Cequa |
| Rxsight INC | $137.77 | 2023 | Rxsight Light Adjustable Lens (Rxlal), Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Shire North American Group INC | $135.63 | 2019 | |
| Amgen INC. | $110.07 | 2025 | Tepezza |
| Lkc Technologies, INC. | $74.34 | 2022 | |
| The Cameron-Ehlen Group, INC. | $72.07 | 2020 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb, A Division of Bausch Health US, LLC | $68.05 | 2019-2021 | |
| Coopervision INC. | $56.66 | 2019-2022 | |
| Dompe US, INC. | $49.70 | 2024-2025 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $31.64 | 2024 | Xdemvy |
| Oyster Point Pharma, INC. | $30.54 | 2022 | |
| Horizon Therapeutics Plc | $25.24 | 2023 | Tepezza |
| Novartis Pharmaceuticals Corporation | $23.65 | 2019 | |
| Harrow Eye, LLC | $17.55 | 2024 | Vevye |
| Eyevance Pharmaceuticals LLC | $17.29 | 2022 | |
| Lumenis, INC | $17.25 | 2021 | |
| Allergan, INC. | $17.11 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicole Kish listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.